Sun Zhenjie, Du Tianyu, Yang Guosheng, Sun Yinghuan, Xiao Xuyang
Department of Thoracic Surgery, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, 121001, China.
Sci Rep. 2025 Jul 2;15(1):22962. doi: 10.1038/s41598-025-04485-4.
Exosomes are crucial in the development of non-small cell lung cancer (NSCLC), yet exosome-associated genes in NSCLC remain insufficiently explored. The present study identified 59 exosome-associated differentially expressed genes (EA-DEGs) from the Gene Expression Omnibus (GEO) and GeneCards databases. Functional analysis indicated the involvement of the EA-DEGs in NSCLC-related pathways, including the cell cycle, DNA replication, and the immune response. Logistic regression, Least Absolute Shrinkage and Selection Operator (LASSO), support vector machine-recursive feature elimination (SVM-RFE), and random forest (RF) models were used to identify four key biomarkers, namely, PAICS, SLC2A1, A2M, and GPM6A, with diagnostic potential. Gene expression, pathological staging, and prognosis were analyzed in the lung adenocarcinoma (LUAD) subtype. Potential drugs targeting these biomarkers were identified, and an RNA-binding protein (RBP) and transcription factor (TF) regulatory network was constructed. Single-sample Gene Set Enrichment Analysis (ssGSEA) analysis highlighted the involvement of changes in the immune microenvironment. A diagnostic model providing new insight into the molecular mechanisms underlying NSCLC is proposed. However, further experimental verification is required to assess its practical value for NSCLC and other lung cancer subtypes before clinical application.
外泌体在非小细胞肺癌(NSCLC)的发展中至关重要,但NSCLC中与外泌体相关的基因仍未得到充分研究。本研究从基因表达综合数据库(GEO)和基因卡片数据库中鉴定出59个与外泌体相关的差异表达基因(EA-DEGs)。功能分析表明,EA-DEGs参与了NSCLC相关通路,包括细胞周期、DNA复制和免疫反应。使用逻辑回归、最小绝对收缩和选择算子(LASSO)、支持向量机递归特征消除(SVM-RFE)和随机森林(RF)模型来识别四个具有诊断潜力的关键生物标志物,即PAICS、SLC2A1、A2M和GPM6A。对肺腺癌(LUAD)亚型进行了基因表达、病理分期和预后分析。确定了靶向这些生物标志物的潜在药物,并构建了一个RNA结合蛋白(RBP)和转录因子(TF)调控网络。单样本基因集富集分析(ssGSEA)突出了免疫微环境变化的参与情况。提出了一个为NSCLC潜在分子机制提供新见解的诊断模型。然而,在临床应用之前,需要进一步的实验验证来评估其对NSCLC和其他肺癌亚型的实际价值。